Roche Holdings Ltd. (RHHBY) reported positive data from a mid-stage trial on trastuzumab emtansine (T-DM1) in treatment-naïve patients with HER2-positive metastatic breast cancer. The phase II trial (TDM4450g) compared trastuzumab emtansine with the combination of Herceptin (trastuzumab) and chemotherapy (docetaxel).
The trial results demonstrated that treatment with trastuzumab emtansine led to a 41% decline in the risk of disease worsening or death in patients in the trastuzumab emtansine … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here